Adipose-derived stem cells and lattices

Patent Number: 7,470,537

The therapeutic benefits of adipose derived stem cells have been demonstrated in animal trials and are currently undergoing several clinical trials.  Although patents have been issued on methods of isolating fat derived stem cells, such as 7,390,484 held by Cytori, or 7,078,232 held by Artecel covering adipose stem cells that have been differentiated into cartilage, the current patent seems to be one of the most potent ones we have seen to date in the adipose area. 

This patent covers specific composition of matter of adipose stem cells.  Unfortunately for the inventors, in the claims the word "isolated" exists.  The interpretation of this single word will have a substantial impact on the value of this patent.  Below we listed the claims. 

 1. An isolated population of stem cells, obtained from human adipose tissue having a CD marker profile comprising a combination of STRO-1+, CD29+, CD44+, CD71+, CD49D+, low or undetectable levels of CD 106, CD90+, and CD105+.

2. An isolated population of stem cells, obtained from human adipose tissue having a CD marker profile comprising (a) STRO-1, (b) CD49d, (c) low or undetectable levels of CD106, and (d) any one or more of CD29, CD44, CD71, CD90, SH3, and CD105, and wherein the CD marker profile further comprises CD31-, and CD45-.

3. An isolated population of stem cells, obtained from human adipose tissue having a CD marker profile comprising a combination of STRO-1+, CD29+, CD44+, CD49D+, low or undetectable levels of CD106, CD71+, CD90+, CD105+, CD31-, and CD45-

View this patent on the USPTO website.